LNG-IUS may have potential in endometrial cancer
Insertion of a levonorgestrel intrauterine system (LNG-IUS) can reverse abnormal endometrial cell growth, according to the results of a small study in high-risk patients, suggesting that the device may have potential in treatment of women with early-stage endometrial cancer who are not candidates for surgery.
Such are the findings from Georgia Health Sciences University Cancer Center researchers who presented the results recently at the International Gynecological Cancer Society’s 14th biennial meeting.
The researchers followed a small group of high-risk patients for 2 years who had early-stage endometrioid adenocarcinoma or atypical endometrial hyperplasia. Each was treated with the LNG-IUS and followed with transvaginal ultrasound (TVS). The endometrial stripe was measured with TVS before the study and at the 3- and 6-month marks. Progressive thinning of the stripe at each stage demonstrated effectiveness of the LNG-IUS. For all patients, subsequent endometrial biopsy found reversal of neoplastic changes.
Further confirming their findings, the researchers also analyzed 13 published studies and found a complete pathological response in 91.3% of the cases. This study validated the use of TVS as a useful follow-up tool in assessing endometrial cancer treatment.
Because traditional treatments for endometrial cancer can result in postoperative complications and morbidity, the researchers hope this can be a lower-risk and more cost-effective way to manage the disease.
Read other articles in this issue of Special Delivery.